The two main types of lung cancer aresmall-cell lung cancerand non-small-cell lung cancer.Non-small-cell lung cancer is a catchall term for all lung cancers that are the not small-cell type. They are grouped together because the treatment is often the same for all non-small-cell types....
THE RELATIONSHIP BETWEEN LUNG FUNCTION AND NON- SMALL CELL LUNG CANCER IN MEN AND WOMENacquired pulmonary lobar emphysemabarotraumaventilation of newbornone-sided high-frequency ventilationMechanical ventilation of preterm and newborn infants is associated with the risk of inducing a pulmonary baro- or ...
Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades, the management of non-small cell lung cancer (NSCLC) has undergone a significant revolution. Since the first identification of activating mutations in the epidermal growth factor receptor (EGFR) gene in...
Non-small-cell lung cancers (NSCLCs) are now appreciated to be a group of heterogeneous diseases. This Review discusses the biology of NSCLCs and what we know about their origins, diversity and the microenvironments surrounding them, with a view towards
Non-small cell lung cancer Micrometastasis Lymph node metastasis Occult metastasis 1. Introduction By the large, lung cancer is the leading cause of cancer-related mortality in the world for both men and women. More than 80% of lung cancers are nonsmall cell lung cancers (NSCLCs). Despite ...
<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d4331941e184">Lung oncogenesis relies on intracellular cysteine to overcome oxidative stress. Several tumor types, including non-small cell lung cancer (NSC
In the past decades, substantial developments in the understanding of molecular biology in non-small-cell lung cancer (NSCLC) have improved diagnosis and treatment of NSCLC based on the genotype of each patient's tumor. For example, gain-of function mutations of epidermal growth factor receptor (...
At the time of diagnosis of non-small cell lung cancer, about two thirds of the patients manifest tumor disease limited to the lungs without distant metastases. In this group localized tumor spread (stages I and II) can be distinguished from locally advanced spread including lymph node metastases...
Find OPDIVO® (nivolumab) efficacy information for the treatment of non-small cell lung cancers. Please see Indications and Important Safety Information.
Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1 on immune cells and PD-L1 on cancer cells have been used to successfully treat non-small cell lung cancer (NSCLC), including some durable responses lasting years. Two drugs, nivolumab and pembrolizumab, are ...